Vaccines Enter the New Age of Adjuvants
This article was originally published in RPM Report
Executive Summary
The US vaccine industry is a year away from a wave of new, more effective and longer-lasting adjuvant-enhanced products. The technology promises added protection to patients-and extra proprietary rights to product marketers.